Gene therapy may be applied for the prevention of AIDS development. The strategy proposed by D. Baltimore (1) , called intracellular immunization, involves taking bone marrow cells from a human immunodeficiency virus-infected individual, genetically engineering the stem cells to become virus resistant by infecting or transfecting them with a virus or DNA construct that encodes RNA or protein capable of interfering with the intracellular growth of human immunodeficiency virus, and injecting the modified stem cells autologously into the patient. However, there are many serious pending questions concerning the gene therapy approach. First of all, what is the gene to be used? It has to be a dominant gene encoding products that inhibit the development of AIDS. Also, when introduced into the stem cells, will the gene be expressed satisfactorily? A still more important question is whether the intracellularly immunized cells actually work to prevent the development of AIDS in vivo, even if a good dominant gene and good methods for gene engineering are developed.
We report an answer to the above questions by using an animal model in which transplantation of intracellularly immunized cells actually prevented the development of AIDS in mice.
Newborn BALB/c and adult C57BL/6 mice infected with LP-BM 5 murine leukemia virus (MuLV) develop a syndrome referred to as MAIDS (2) . However, newborn BALB/c-Fv-4w/ mice, which are congenic BALB/c mice carrying the resistance allele of the Fv-4 gene, were completely resistant to MAIDS virus as well as to infections with Moloney and Friend MuLVs (7) . The Fv-4r gene was first reported in a G-strain mouse with resistance to Friend MuLV infection (8) . A congenic BALB/c mouse strain with the Fv-4r gene was established by mating a BALB/c mouse with a wild mouse carrying the Fv-4r gene (7).
The Fv-4 gene was molecularly cloned and reported to consist mainly of a truncated MuLV env-like sequence (3, 5, 6 explained by a model of receptor interference by the Fv-4r gene product (5) .
In this paper, in order to examine whether the Fv-4r gene is effective for gene therapy of MAIDS, we transplanted bone marrow cells from BALB/c-Fv-4wr mice to BALB/c and C57BL/6 mice infected with the MAIDS virus.
MATERIALS AND METHODS
Virus. MAIDS virus used for mouse inoculation was the culture fluid harvested from a G6 line of SC-1 cells containing the defective genome and nondefective LP-BM5 ecotropic virus, which was obtained from J. Hartley (2) .
Mice. A congenic strain, BALB/c-Fv-4w, which was established by the introduction of the gene Fv-4wr from a Mus musculus molossinus strain into the genetic background of BALB/c mice, was supplied by T. Odaka (7) . Mice were inoculated intraperitoneally with the culture medium harvested from a G6 cell line containing MAIDS virus by using a 1.0-ml inoculum for adult mice and a 0.1-ml inoculum for newborn mice.
Antiserum. Anti-Fv-4 serum was prepared in BALB/c mice immunized with spleen cells of BALB/c-Fv-4w' mice (11 
RESULTS
Sensitivity of BALB/c-Fv-4wr mice to the MAIDS virus in vivo and vitro. Newborn and adult BALB/c-Fv-4w' mice were inoculated with MAIDS virus. Although adult mice of the BALB/c strain were resistant to MAIDS, newborn mice were highly sensitive. However, all BALB/c-Fv-4w' mice, adults and newborns, inoculated with MAIDS virus did not develop MAIDS. To examine whether the difference in susceptibility was related to the difference in replication of the MAIDS virus, spleen cells collected from individual mice 1, 4, and 16 weeks after infection were assayed for infectious centers by using SC-1 cells and the XC plaque assay method (2) , by which the replication of the ecotropic helper viral component of MAIDS virus was detected. Little or no replication of ecotropic MuLV was detected in BALB/c-Fv-4w' mice (Table 1 ). These data suggested that there was no replication of the pathogenic defective virus either. To compare the viral replication in BALB/c and BALB/c-Fv-4W cells in vitro, secondary embryonic cells were infected with MAIDS virus. Figure 1 (Fig. 2A) . When bone marrow cells from syngeneic BALB/c mice were transplanted into the 45-day-old infected mice, the recipient mice survived slightly longer than infected mice which did not undergo transplantation. However, most of the mice which received bone marrow cells from syngeneic BALB/c mice developed MAIDS a little later (Fig. 2B) . The replication of the virus in the mice which received syngeneic bone marrow cells (those whose survival data are shown in Fig. 2B ) was almost as high as the replication in the mice whose survival data are shown in Fig. 2A (data not shown). When infected BALB/c mice were given an intravenous injection of 107 bone marrow cells from BALB/c-Fv'-4w' mice after receiving 7.5 Gy of cobalt irradiation, the survival of recipient mice was much longer than that of the untreated mice (Fig. 2C) . The replication of the virus in the spleens of mice given bone marrow transplants from Fv-4wr mice was examined by the infectious-center assay 4 and 16 weeks after transplantation. However, no viral replication was detected in the mice given bone marrow transplants from Fv-4wr mice. were chimeric for BALB/c and BALB/c-Fv-4wr mice (Fig. 3C) . However, the replication of the virus in the spleen cells of the chimeric mice whose data are shown in Fig. 3C was not detected by the infectious-center assay. Further tests for detection of viral replication in the other chimeric mice are necessary. On the contrary, spleen cells of the surviving recipient mouse were found to be mainly of BALB/c-Fv-4w' mouse origin when analyzed 5 months after transplantation (Fig. 3D) . Another cause of the earlier death of recipient mice was pneumonia.
Transplantation of bone marrow cells to MAIDS virusinfected C57BL/6 mice. One-month-old C57BL/6 mice were infected with MAIDS virus. All mice developed MAIDS within three months, and more than 85% of them died within 5 months after infection (Fig. 4A) . When syngeneic C57BL/6 bone marrow cells were transplanted 2 weeks after infection into the infected mice after they had received 10 Gy of cobalt irradiation, the recipient mice survived slightly longer than infected mice which did not undergo transplantation. However, all mice which received syngeneic C57BL/6 bone marrow cells developed MAIDS a little later (Fig. 4B) . However, when infected C57BL/6 mice were given an intravenous injection of 107 bone marrow cells from BALB/c-Fv-4w' mice after receiving 10 Gy of cobalt irradiation, the recipient mice survived much longer than infected mice which did not undergo bone marrow transplantation (Fig. 4C) . However, 4 of the 20 mice which received bone marrow cells from BALB/c-Fv-4wr mice developed MAIDS with splenomegaly and lymphoadenopathy. From such MAIDS mice, replication of MAIDS virus in spleens was detected (data not shown). Of the 20 mice, 2 died of thymoma. FACS analysis with H-2 antibodies showed almost the same results as in the case of BALB/c mice (Fig. 5) . Spleen cells of the surviving recipient mice were found to be chimeric, of BALB/c-Fv-4wr origin, when analyzed 5 months after bone marrow transplantation (Fig. SD) . However, spleen cells of the recipient mice with MAIDS were C57BL/6 cells (Fig. SC) . BALB/c-Fv-4wr mouse bone marrow cells were transplanted to C57BL/6 mice 2 months after MAIDS virus infection when Fig. 2 and 4, the life span of uninfected mice which had undergone bone marrow transplantation was undoubtedly shorter than that of the normal mice which did not undergo transplantation. The shorter life span seems to be an effect of cobalt irradiation. Despite the side effects caused by 10 Gy of whole-body irradiation in C57BL/6 mice, such as fading of coat color, decrease in body weight, cataracts, sterility, and thymomas, bone marrow transplantation showed good efficacy in prolonging the life span of infected mice. If the Fv-4 gene can be introduced into syngeneic bone marrow cells by gene transfer methods such as the retrovirus vector method, cobalt irradiation may be omitted in some cases, as in the case of BALB/c MAIDS mice, in which no leukemia cells were detected.
